Hodgkin-limfóma: vizsgálatok itt: Németország
17 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Berlin, Cologne, Magdeburg
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - 1/2. fázisTaking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Essen, Giessen, Munich, Wuerzburg
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - 1/2. fázisTaking peopleA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Muenster
- Életkor
- Up to 17 év
- People
- 37 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2023-504264-41-00 · EU 2023-504264-41-00 - 1. fázisTaking peopleA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Cologne, Essen, Frankfurt Am Main
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - 2. fázisTaking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Berlin, Chemnitz, Essen, Jena, Wuerzburg
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - 1/2. fázisTaking peopleAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Where
- Berlin, Cologne, Erlangen, Würzburg
- Életkor
- 12 év and over
- People
- 161 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00 - 2. fázisTaking peoplePREFer
- Where
- Aachen, Berlin, Bielefeld, Bonn, Bremen, Brunswick, Chemnitz, Cologne, Darmstadt, Dresden, Erlangen, Essen, Esslingen am Neckar, Flensburg, Frankfurt Am Main, Fulda, Giessen, Hamburg, Hamm, Heidelberg, Homburg, Jena, Karlsruhe, Kempten (Allgau), Leipzig, Luebeck, Luedenscheid, Moenchengladbach, Munich, Offenburg, Paderborn, Regensburg, Rostock, Siegen, Stade, Stuttgart, Trier, Ulm, Villingen-Schwenningen, Wuerzburg
- Életkor
- 18 év and over
- People
- 50
- Run by
- University Of Cologne
See details and how to joinNCT06916416 · EU 2024-520138-31-00 - 1/2. fázisTaking peopleQUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers
- Where
- Berlin, Dresden, Erlangen, Essen, Hamburg, Marburg, Munich, Ulm
- Életkor
- 18 év and over
- People
- 60
- Run by
- Avencell Therapeutics Inc.
See details and how to join2025-521735-36-00 · EU 2025-521735-36-00 - 1/2. fázisTaking peopleA study to evaluate safety and clinical activity of GSK5926371 in adult participants with relapsed or refractory B-NHL
- Where
- Freiburg im Breisgau, Mainz
- Életkor
- 18 év and over
- People
- 30 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2025-524915-36-00 · EU 2025-524915-36-00 - 1/2. fázisTaking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- Muenster, Tuebingen
- Életkor
- 6 hónap to 17 év
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - 3. fázisTaking peopleAcalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
- Where
- Aachen, Aalen, Amberg, Augsburg, Bamberg, Bayreuth, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Eberswalde, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt (Oder), Giessen, Greifswald, Halle Saale, Hamburg, Heilbronn, Hildesheim, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Magdeburg, Minden, Muenster, Munich, Neuss, Nuremberg, Paderborn, Rheine, Rostock, Saarbruecken, Saarlouis, Siegen, Stuttgart, Traunstein, Trier, Ulm, Wolfsburg, Wuppertal
- Életkor
- 61 év and over
- People
- 330 worldwide
- Run by
- Universität des Saarlandes
See details and how to joinNCT05820841 · EU 2022-501187-18-00 - 3. fázisTaking peopleA trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.
- Where
- Frankfurt (Oder)
- Életkor
- 18 év and over
- People
- 132 worldwide
- Run by
- Regeneron Pharmaceuticals Inc.
See details and how to joinNCT06230224 · EU 2022-502783-21-00 - 1/2. fázisTaking peoplePhase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
- Where
- Frankfurt am Main, Stuttgart
- Életkor
- 18 év and over
- People
- 23 worldwide
- Run by
- BioInvent International AB
See details and how to joinNCT03571568 · EU 2024-512972-36-00 - 2. fázisTaking peoplePembro-FLASH
- Where
- Berlin, Bremen, Chemnitz, Cologne, Essen, Frankfurt Am Main, Goettingen, Hamburg, Munich, Stuttgart
- Életkor
- 18 év to 64 év
- People
- 40
- Run by
- University Of Cologne
See details and how to joinNCT06045159 · EU 2022-501458-13-01 - 2. fázisNot yet taking people in NémetországPhase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
- Where
- Berlin, Bremen, Cologne, Essen, Hamburg, Heidelberg, Munich
- Életkor
- 18 év to 60 év
- People
- 35
- Run by
- University of Cologne
See details and how to joinNCT06919679 · EU 2025-521749-26-00 - 2. fázisNot yet taking people in NémetországPembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
- Where
- Cologne
- Életkor
- 18 év to 60 év
- People
- 40
- Run by
- University of Cologne
See details and how to joinNCT06045195 - 1/2. fázisTaking peopleTreatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
- Where
- Heidelberg
- Életkor
- 3 év and over
- People
- 68
- Run by
- University Hospital Heidelberg
See details and how to joinNCT03676504 · EU 2024-516832-82-00